Investment of approx. JPY 700 million (USD 4.4 million¹) for preclinical development of an antimalarial drug

Malaria is a serious infectious disease that affects more than 280 million people and claims approximately 610,000 lives worldwide each year. Over 95% of all malaria cases occur in Africa, with more than 75% of those affected being children under the age of 5.³ Countermeasures against Plasmodium falciparum malaria, which has a particularly high case fatality rate, and Plasmodium vivax malaria, which is prevalent in Southeast Asia and the Americas, are an urgent priority. To end the epidemics of malaria, new drugs with novel modes of action which overcome known resistance associated with existing therapeutics are needed. It is crucial to develop compounds that can block transmission and be used for chemoprevention, acute treatment, and treatment of relapsing malaria are especially valuable to drive eradication.

To address this issue, the GHIT Fund is investing approximately JPY 700 million (USD 4.4 million¹) in a global partnership aimed at the preclinical development of an antimalarial drug which could be used for treatment, chemoprevention or Single Encounter Radical Cure and Prophylaxis (SERCAP) of malaria. This project is being led by Medicines for Malaria Venture (MMV), Tanabe Pharma Corporation in Japan, and the University of Georgia in the United States. The investment builds on a prior GHIT-supported project³ that received approximately JPY 600 million (USD 3.8 million¹) between 2015 and 2025. Through this project, there is also the prospect of developing a long‑acting injectable that can provide three or more months of protection against recurrent Plasmodium vivax malaria.

Investment of approx. JPY 330 million (USD 2 million¹) in global evaluation in Kenya, Senegal and India and regulatory registration for Eumycetoma

Eumycetoma is a severely neglected tropical disease that causes chronic, destructive infections, often leading to disability, amputation, loss of income, and social stigma. It affects tens of thousands of people in resource-constrained rural communities across Africa, Asia, and Latin America, with the highest burden reported in the so-called “mycetoma belt” between latitudes 15° S and 30° N. Although underreported, global estimates suggest that more than 100,000 people may be living with the disease, with thousands of new cases annually. Despite its significant impact, current treatments remain limited and are often toxic and poorly tolerated.

The GHIT Fund has been investing in a collaboration between Eisai Co., Ltd. and Drugs for Neglected Diseases initiatives (DNDi) to develop a treatment for mycetoma since 2017. This support began with a Phase II randomized clinical trial conducted in Sudan and, since 2023, has extended to supporting the registration of fosravuconazole based on the trial results as well as a cohort study providing controlled early access to fosravuconazole for patients with eumycetoma in Sudan. To the best of our knowledge, no drug for mycetoma has been evaluated through randomized controlled trials in patients diagnosed with the disease prior to the initiation of the GHIT Fund-supported trial in Sudan.

Building on the results obtained in the study, the GHIT Fund has decided to invest approximately JPY 330 million (USD 2 million¹) in a project to conduct multi-country, open‑label clinical trials in Kenya, Senegal, and India to generate additional evidence for the WHO recommendation and regulatory registration of fosravuconazole for eumycetoma. The new trial will address limitations of the earlier study, including small sample size, single‑country population, and limited pathogen diversity.

In addition, the GHIT Fund will invest a total of approximately JPY 340 million (approx. USD 2.1million¹) in the following three R&D projects:

1. Prolyl tRNA synthetase inhibitors as a new antimalarial project led by MMV, GSK (GlaxoSmithKline Investigacion y Desarrollo, S.L.), and the University of Tokyo.
2. Hit-to-Lead project for an antimalarial drug led by MMV and DAIICHI SANKYO COMPANY, LIMITED.
3. Screening project for antimalarial drugs that inhibit Serine Hydroxymethyltransferase (SHMT) led by Eisai Co., Ltd. and MMV.

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.

As of March 31, 2026, there are 42 ongoing projects, including 20 discovery projects, 13 preclinical projects, and 9 clinical trials⁵ in the GHIT Fund’s portfolio. The total amount of investments since 2013 is JPY 43.9 billion (USD 274 million¹) (Appendix 2).

¹ USD 1 = JPY 159.90, the approximate exchange rate on March 31, 2026.

² These awarded projects were selected and approved as new investments from among proposals to RFP2023-001, RFP2025-001 and RFP2025-002 for the Target Research Platform, the Screening Platform, the Hit-to-Lead Platform, and the Product Development Platform, , which were open for applications from October 2022 to June 2025.

³ WHO: https://www.who.int/news-room/fact-sheets/detail/malaria

⁴ Project details: G2023-104 https://www.ghitfund.org/investment/portfoliodetail/detail/211/

G2018-202: https://www.ghitfund.org/investment/portfoliodetail/detail/136

H2016-101: https://www.ghitfund.org/investment/portfoliodetail/detail/93

S2014-212: https://www.ghitfund.org/investment/portfoliodetail/detail/56

⁵ This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.

https://www.ghitfund.org/

Appendix 1. Project Details    

ID: G2025-102

ID: G2025-211

ID: G2022-210

ID: H2025-102

ID: S2025-111

*All amounts are listed at an exchange rate of USD 1 = JPY 159.90, the approximate exchange rate on March 31, 2026.

Appendix 2. Investment Overview (as of March 31, 2026)

Investments to date

Total investments: JPY 43.9 billion (USD 274 million¹)

Total invested projects: 146 (42 active projects and 104 completed projects)

To learn more about the GHIT Fund’s investments, please visit

Investment Overview: https://www.ghitfund.org/investment/overview/en

Portfolio: https://www.ghitfund.org/investment/portfolio/en

Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en

Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en 

For more information, contact:

Katy Lenard at +1-301-280-5719 or klenard@burness.com 

Eriko Mugitani at +81-36441-2032 or eriko.mugitani@ghitfund.org 

View original content:https://www.prnewswire.co.uk/news-releases/total-investment-of-approx-usd-8-5-million-in-malaria-and-ntd-rd-projects-with-partners-including-mmv-gsk-tanabe-pharma-eisai-and-dndi-302748078.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

NEW YORK, April 21, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on April 21st

• The major averages are climbing Tuesday morning as investors react to the latest developments in Iran and fresh earnings.
• UiPath (NYSE: PATH) CMO Michael Atalla will join NYSE Live to discuss his company’s five-year anniversary as a listed company.
• HSBC (NYSE: HSBC) Innovation Banking Managing Director Jonathan Norris will join NYSE Live to discuss the state of VC healthcare,
• Suburban Propane Partners (NYSE: SPH) CEO Michael Stivala will join Taking Stock after market close as his company celebrates its 30^th listing anniversary.

Opening Bell

UiPath (NYSE: PATH) celebrates the 5^th anniversary of its IPO

Closing Bell

Suburban Propane (NYSE: SPH) celebrates the 30^th anniversary of listing

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Video – https://mma.prnewswire.com/media/2961882/NYSE_Market_Update_April_21.mp4 

Photo – https://mma.prnewswire.com/media/2961881/NYSE_CNS_Photo.jpg 

Logo – https://mma.prnewswire.com/media/2581322/5928649/New_York_Stock_Exchange_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-update-uipath-celebrates-five-year-listing-anniversary-at-nyse-302748704.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

OAKBROOK TERRACE, Ill., April 21, 2026 /PRNewswire/ — Joint Commission International (JCI) today launched the nomination process for its inaugural JCI Global Patient Safety Awards, which aim to celebrate and recognize excellence in patient safety and healthcare quality efforts internationally, as well as stimulate global knowledge sharing and learning. Nominations for the awards will be accepted through 8 June 2026. Details about the submission process can be found on JCI’s website: https://jointcommission.org/en/about-us/recognizing-excellence/global-patient-safety-awards

The JCI Global Patient Safety Awards will recognize and elevate real-world, high impact patient safety practices outside the U.S. for two audiences:

• Any healthcare organization that provides patient care, including:
  • Hospitals/health systems
  • Ambulatory/outpatient centers
  • Community/rural facilities
  • Academic/specialty care center
• National health authorities or Ministries of Health that have implemented patient safety initiatives at a system, regional, or national level

The program will elevate innovative practices that demonstrate measurable improvements in patient outcomes and showcase adaptable solutions for all types of healthcare organizations, including those in low-resource environments. Submissions will be evaluated based on cost-effectiveness to implement, resource burden, novelty, impact, transferability and scalability. Healthcare organizations do not need to be accredited by JCI to be eligible. All practices submitted must be actionable and measurable in real-world clinical settings.

“The JCI Global Patient Safety Awards align closely with our ongoing mission to elevate healthcare quality and safety worldwide,” said Jonathan B. Perlin, MD, PhD, president and CEO, Joint Commission Enterprise. “These awards are designed to spotlight organizations and health authorities globally whose commitment to patient safety is commendable and also replicable across other regions and resource settings. By publishing and distributing best practices from the winners, we will spark inspiration and progress, ultimately accelerating meaningful improvements for patients everywhere.”

“Recognition plays an important role in sustaining momentum. JCI Global Patient Safety Awards will acknowledge frontline, system‑level and national efforts, and signal leadership commitment to patient safety as a core value,” said Neelam Dhingra, MD, MBBS, vice president and global chief patient safety officer, JCI. “What often stands in the way to improving patient safety is access to knowledge, proven practices, and resources. These awards are designed to celebrate innovation, but more importantly they are designed to offer a framework for gathering and sharing leading practices that all can learn from.”

The winners will be honored at the annual Joint Commission UNIFY 2026 conference, held 30 September–1 October 2026, in Washington, DC, United States.

Healthcare organizations and national health authorities outside the United States are eligible to apply for the awards at no cost. Interested parties can access application criteria, more information, and the link to apply on JCI’s website HERE.

About Joint Commission International

Joint Commission International (JCI), established in 1994, is a nonprofit affiliate of Joint Commission, dedicated to improving healthcare quality and patient safety worldwide. Through international accreditation and certification, advisory services, publications, and education programs, JCI works with healthcare organizations, public health agencies, and health ministries in more than 80 countries to enable and affirm the highest standards of healthcare quality and patient safety for all.

Learn more at https://www.jointcommission.org/en

Media Contact

Hannah Miller

Corporate Communications

(630) 792-5174

press@jointcommission.org

Logo – https://mma.prnewswire.com/media/118169/5924869/joint_commission_international_logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/joint-commission-international-launches-global-patient-safety-awards-to-recognize-innovative-healthcare-practices-and-excellence-302747962.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

Virtuosi helps biopharmaceutical manufacturers to solve one of their most critical operational challenges—the readiness of the workforce to perform in high-risk, high-complexity GMP environments—by building and sustaining operational capability across the employee lifecycle.

Under this agreement, Vienni will be QxP’s exclusive partner for Virtuosi in India, leading market engagement, client identification, and commercial activities.

Vi’eNnI^® TRAINING & CONSULTING LLP: Enabling Scalable Training Excellence Across India

Vi’eNnI^® is a recognized leader in pharmaceutical training and capability development in India, with a strong track record in GMP education, regulatory compliance, and industry engagement. Vi’eNnI^® through its association with Eduoriens Skill Development LLP and professional bodies such as Parenteral Drug Association (PDA) India, Vienni operates at the center of India’s pharmaceutical training and compliance ecosystem.

With this established network, operational credibility, and relationships across India’s leading pharmaceutical manufacturers, Vienni is uniquely positioned to drive the adoption of Virtuosi at scale across the Indian market.

“This alliance is intended to deepen, enrich, and embed the field of training. The advantage of this collaboration is expected to make learning stick, with recall much higher when a participant leaves the learning zone,” said Vishal Sharma, Co-Founder Director, Vi’eNnI^® TRAINING & CONSULTING LLP

“This marks the beginning of driving innovation and shaping outcomes that matter. Together, we forge a partnership that speaks the language of impact, influence, and enduring progress for teaching-learning & implementation,” said Ivy Louis, Founder Director, Vi’eNnI^® TRAINING & CONSULTING LLP

“Vi’eNnI^®‘s mission is to empower doers to excel in their craft. This association with QxP for Virtuosi marks a pivotal step in advancing workforce capability and highlighting the strategic value of immersive training in India. We are proud to continue driving this mission forward.”

“We are honored to partner with Vi’eNnI^® , a highly respected organization with deep roots in the Indian pharmaceutical industry,” said Crystal Mersh, Chief Executive Officer of Quality Executive Partners, Inc. “Together, we are enabling broader access to Virtuosi in a way that allows clients to build and sustain the knowledge, skills, and behaviors required to perform under real operating conditions. This embeds compliance and capability into daily execution in order to deliver high quality medicines to patients around the world.”

Virtuosi by QxP: Advancing Workforce Capability in India’s Globally Critical Pharmaceutical Hubs

India is one of the most critical pharmaceutical manufacturing markets globally and is poised for significant growth in the coming years, particularly across biologics, biosimilars, and advanced therapies. As manufacturers expand into more complex product categories and face increasing scrutiny from global regulatory agencies—including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) —the ability to rapidly build, standardize, and sustain a high-performing, inspection-ready workforce has become a strategic priority.

cGMP experts at QxP created Virtuosi to address this exact challenge. Virtuosi is an immersive workforce readiness program accredited by the International Accreditors for Continuing Education and Training (IACET), aligning with globally recognized standards for continuing education and distinguishing it as the only virtual reality–based training program to achieve such accreditation.

Combining virtual reality interactive experiences with digital course content, Virtuosi enables professionals to practice critical manufacturing and quality processes—such as aseptic operations, microbiology, and advanced therapies—in realistic, risk-free environments. The platform includes over 100 hours of education, 56 technical courses, and 20 immersive VR experiences, and is available in seven languages—English, French, German, Italian, Mandarin, Spanish, and Swedish—to support global workforce standardization. Virtuosi helps organizations reduce human error, accelerate time to competency, and improve compliance and operational performance across global pharmaceutical operations.

By shifting training from passive instruction to experiential learning, Virtuosi helps reduce time to competency and human error, improve inspection readiness, and drive measurable quality outcomes which translates directly to revenue protection and growth. This partnership strengthens not only the competitiveness of individual organizations, but also the long-term resilience, regulatory standing, and global leadership of India’s pharmaceutical sector.

About Quality Executive Partners, Inc.^® (QxP)

Quality Executive Partners, Inc. (QxP) is a premium CGMP consulting firm focused on solving complex operational and regulatory challenges in pharmaceutical manufacturing. QxP services pharmaceutical manufactures and CDMOs globally across all major modalities – OTC, oral solid dosage, sterile, biologics, ATMPs, clinical-stage manufacturing, and combination products. We support clients throughout the product lifecycle, including clinical operations, commercial readiness, regulatory strategy, quality transformations, and remediation. Through our ‘Teach and Do^®‘ model, QxP embeds senior GMP experts / former regulators into day-to-day operations to execute alongside client teams and build internal capability. This model ensures solutions are effective in practice, sustainable, and directly reduce operational risk. .

About Vi’eNnI^®

Vi’eNnI^® Training and Consulting LLP is a pharmaceutical training and consulting organization based in Bengaluru, India, focused on advancing workforce capability, regulatory compliance, and operational excellence across the life sciences sector, for the past 16 years. The company delivers targeted training and consulting services across GMP, quality systems, aseptic processing, microbiology, and inspection readiness, competency and culture building initiatives, helping organizations strengthen performance, consolidate efficiency and achieve sustainable compliance. Known for its practical, implementation-focused approach, Vi’eNnI^® enables pharmaceutical and biotechnology companies to translate training into measurable improvements on the shop floor, supporting continuous improvement and long-term capability development across India’s pharmaceutical industry with a variety of options and tools.

Media Contact (Global)

Robin Mersh

SVP, Virtuosi Sales

Quality Executive Partners, Inc.

Email: RobinMersh@QualityExecutivePartners.com

Phone: (+1) 678-496-7503

Media Contact (India)

Ivy Louis

Founder-Director

Vi’eNnI^® Training and Consulting LLP

Email: Ivy_louis@vienni.com

Phone: +91 9986821045

WhatsApp: +91 9986821045

Vi’eNnI^® & Virtuosi^® are registered trademarks for VIENNI & Quality Executive Partners, Inc., respectively.

Logo – https://mma.prnewswire.com/media/2790799/5926395/Virtuosi_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/quality-executive-partners-inc-announces-exclusive-partnership-with-vienni-training-and-consulting-llp-to-accelerate-workforce-development-in-indias-huge-pharmaceutical-sector-with-virtuosi-302748013.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

CHENNAI, India, April 20, 2026 /PRNewswire/ — MGM Healthcare, a leading quaternary care hospital in Chennai, has built the world’s largest intestinal rehabilitation and transplant program from scratch in a record three years. Since its inception, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone, the highest annual volume reported anywhere in the world.

The program was conceived three years ago under the leadership of Prof. Dr. Anil Vaidya, Chair and Director, Institute of Multi-Visceral and Abdominal Organ Transplant, following his return from the Cleveland Clinic in the United States. A multidisciplinary team comprising Dr. Senthil Muthuraman, Dr. Venkatesh BS, Dr. Sivakumar Mahalingam, and Dr. Manoj Prabhakar has worked in close coordination with intensivists and anaesthetists Dr. C. P. Dinesh Babu, Late Dr. Nivash Chandrashekar, and Dr. Saravanan to build and scale the program into a comprehensive service.

Commenting on the success of the program, Prof. Dr. Anil Vaidya said, “Intestinal rehabilitation and transplantation is among the most complex and resource-intensive domains in medicine. It replaces the failing intestine with a donor organ, restoring the body’s ability to absorb nutrients naturally. By building the world’s largest program in this domain, we have positioned Chennai as a global reference point. This was not just about creating a transplant program, but an integrated ecosystem spanning surgery, rehabilitation, home-based care, infection control, and long-term monitoring.”

The program has achieved world-class one- and three-year survival rates, with outcomes that rival, and often exceed, leading centres in the United States and Europe. Success is not defined merely by surgical survival, but by freedom from total parenteral nutrition (TPN), a method of delivering nutrition directly into the bloodstream, immune stability, and long-term functional recovery. Crucially, 98% of patients are free from TPN. Given the risks of long-term TPN, including infections, liver damage, and poor quality of life, this reflects true physiological recovery and a return to normal living.

Prof Dr. Vaidya pointed out that beyond scale and outcomes, the program has also expanded the very boundaries of what intestinal transplantation can achieve. It has led to the founding of India’s first Transplant Oncology program, and the world’s third of its kind, where intestinal transplantation is offered as a curative option for patients with inoperable pseudomyxoma peritonei. This represents a paradigm shift: moving transplantation beyond organ failure into the domain of complex malignancy, where conventional surgical options are exhausted. For a disease historically considered terminal in its advanced stages, this approach opens a new therapeutic frontier.

He added, “At the core of this program’s success are three defining innovations. The first is the establishment of a robust, home-based total parenteral nutrition (HPN) program, which supports patients outside the hospital setting. The second is the introduction of a novel, patented antiseptic solution, known as Dorbimex, used as a spray for central line care. When combined with meticulous protocols in catheter maintenance, stoma care, and wound management, this innovation has driven central line infection rates to near zero. A third, and defining differentiator of this program, has been the development of a specialised critical care transport network – the ‘Back to Base’ model. Patients with acute intestinal loss are now safely transferred to Chennai from across India, including Mumbai, Delhi, Agra, Kolkata, and Goa, thanks to across air, road, and even train-based critical care transport, a first-of-its-kind initiative in India.”

Prof. Dr. Vaidya highlighted that intestinal failure is a systems problem, requiring synchronised expertise across nutrition, immunology, infection control, critical care, and surgery. “What has emerged is more than a clinical program – it reflects how high-complexity care can be thoughtfully designed and scaled in India. It also underscores that innovation in care delivery, not just technology, is critical to improving outcomes, and that leadership in advanced medicine is no longer limited by geography.”

MGM Healthcare is one of India’s leading multi-specialty hospital chains. Its flagship facility in Chennai is a 400-bed, LEED Platinum and JCI-certified hospital, reflecting a strong focus on high-acuity care and advanced clinical infrastructure. With the launch of the MGM Cancer Institute in 2023, the group offers multidisciplinary cancer care under a dedicated platform.

MGM Malar in Adyar brings over three decades of trusted clinical excellence, while MGM Healthcare SevenHills is expanding the group’s footprint in Andhra Pradesh with a 300-bed tertiary care centre. Complementing this growth is the upcoming 275-bed MGM unit in Alwarpet, Chennai, designed to deliver advanced, integrated care.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/mgm-healthcare-sets-up-worlds-largest-intestinal-rehab–transplant-program-in-chennai-in-three-years-302746897.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

Gene Therapies for Inherited Blindness, Sickle Cell Disease and Beta-Thalassemia

Discovery of Key Genetic Cause of ALS and Frontotemporal Dementia

Precision Measurement of Muon’s Magnetic Moment

Advances in Mathematics of Waves and Nonlinear Systems

Special Prize for Pioneer of Theory of Strong Nuclear Force

Breakthrough Prize in Life Sciences Awarded to Jean Bennett, Katherine A. High and Albert Maguire; Stuart H. Orkin and Swee Lay Thein; Rosa Rademakers and Bryan Traynor

Breakthrough Prize in Mathematics Awarded to Frank Merle

Breakthrough Prize in Fundamental Physics Awarded to Muon g-2 Collaborations at CERN, Brookhaven National Laboratory, and Fermilab

Special Breakthrough Prize in Fundamental Physics Awarded to David J. Gross

Inaugural Vera Rubin New Frontiers Prize Awarded to Carolina Figueiredo

Six New Horizons Prizes Awarded for Early-Career Achievements in Physics and Mathematics

Three Maryam Mirzakhani New Frontiers Prizes Awarded to Women Mathematicians for Early-Career Work

Laureates to be Celebrated Tonight at Breakthrough Prize Ceremony in Los Angeles

LOS ANGELES, April 18, 2026 /PRNewswire/ — The Breakthrough Prize Foundation today announced the winners of the 2026 Breakthrough Prizes, honoring scientists whose discoveries are significantly driving growth of human knowledge. In the Life Sciences, their work has led to gene therapies for three devastating diseases – inherited blindness, sickle cell disease and beta-thalassemia, and identified a key genetic cause of two more – ALS and frontotemporal dementia. In Physics and Mathematics, they have constructed theories of the fundamental forces of nature and probed them to mind-blowing precision, and revealed deep truths about the mathematical behavior of waves.

The Breakthrough Prizes – popularly known as the “Oscars® of Science” – were created to celebrate the wonders of our scientific age. Co-founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Julia and Yuri Milner, and Anne Wojcicki, the prizes are now in their 14^th year.

This year, six Breakthrough Prizes of $3 million each were awarded. In addition, the Foundation recognized 15 early-career physicists and mathematicians, who share six $100,000 New Horizons Prizes. Three women mathematicians recently completing PhDs each receives a $50,000 Maryam Mirzakhani New Frontiers Prize.

This year’s prize money totals $18.75 million, bringing the amount conferred over the 15 years of the Breakthrough Prize to more than $340 million.

“This year’s laureates show what great science can do — deepen our understanding of the world and lead to discoveries that improve millions of lives,” said Mark Zuckerberg and Dr. Priscilla Chan, founders of Biohub. “We’re proud to recognize their work.”

“The brilliant scientists who win the Breakthrough Prize,” said Yuri Milner, co-founder of Breakthrough Prize Foundation, “Are building a cathedral of knowledge on foundations laid down by the giants who came before them. We owe our civilization – and its future – to them.”

Breakthrough Prize in Life Sciences

Jean Bennett, Katherine A. High and Albert Maguire share the Breakthrough Prize in Life Sciences. This prize recognizes work that led to the first FDA–approved gene replacement therapy. It has transformed the lives of people born with Leber congenital amaurosis, a rare inherited retinal disease that usually results in total blindness in early adulthood, enabling children who had been going blind to gain their independence, attend regular schools, play outside at night, and in some cases even qualify for driver’s licenses. The therapy replaces the defective RPE65 gene, which produces a malfunctioning version of a protein critical to the visual cycle – the process by which the retina responds to light. The husband-and-wife team of molecular biologist Bennett and ophthalmic surgeon Maguire invented and developed the therapy from first conception to an effective treatment in animal models (including restoring sight to a number of Swedish Briard dogs which they went on to adopt). In 2005, High, a physician-scientist at Children’s Hospital of Philadelphia (CHOP) invited Bennett and Maguire to collaborate on a human trial. High’s laboratory and clinical gene therapy expertise proved crucial in the development of the approved drug, including gaining regulatory approval to conduct the initial clinical trials, and in directing the production and characterization of high-quality viral vector preparations used to introduce the replacement gene. The three physician-scientists worked together to design the pivotal trial, including developing and validating a novel clinical endpoint to measure the vector’s clinical effect.

Nearly all eligible Leber congenital amaurosis patients with RPE65 mutations in the United States have now been treated, and many others around the world are now gaining access to the therapy. The benefits have proved durable, with patients treated over a decade ago maintaining stable vision improvements. More broadly, this discovery demonstrated that the technology could work safely and effectively, establishing regulatory pathways and manufacturing approaches that opened the door to gene therapy approvals for a range of genetic diseases. Since their pioneering work, hundreds of trials, including over 100 retinal gene therapy trials have been conducted, with more than half a dozen currently in late-stage clinical testing.

Stuart H. Orkin and Swee Lay Thein share the Breakthrough Prize in Life Sciences. Their research transformed the devastating blood disorders sickle cell disease and beta-thalassemia from incurable to treatable conditions through gene editing therapy.

In beta-thalassemia the body fails to produce enough healthy hemoglobin; while in sickle cell disease, defective hemoglobin causes red blood cells to become stiff, sticky and sickle-shaped. But people who produce elevated levels of fetal form of hemoglobin as adults, rather than switching entirely to adult hemoglobin, have much milder forms of the diseases. This presented a tantalizing possibility for translational medicine: genetically switching fetal hemoglobin production back on, and so mitigating disease symptoms. Thein mapped the trait of persistent fetal hemoglobin production to chromosome 2, and subsequently identified the gene BCL11A as the key genetic player. Orkin demonstrated that BCL11A functions as the master repressor of fetal hemoglobin, shutting down its production after birth, and that inactivating it restored fetal hemoglobin production in mice and eliminated sickle cell disease symptoms. His laboratory identified a specific DNA enhancer region that controls BCL11A expression itself, but crucially only in red blood cells, providing a precise and safe target for therapeutic intervention without affecting other cells.

The translation of these discoveries into a CRISPR-based gene therapy (Casgevy) that edits this enhancer region in patients’ own blood stem cells resulted in the first CRISPR-based medicine approved for any disease. This work has revolutionized treatment for sickle cell disease and beta-thalassemia, providing a potentially curative one-time therapy for conditions affecting millions worldwide.

Rosa Rademakers and Bryan Traynor independently solved a decades-old mystery in neurodegenerative disease by discovering the most common genetic cause of both amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and frontotemporal dementia (FTD), the second leading cause of early-onset dementia. Through multi-year, international collaborations, they collected large-scale data from families where both ALS and FTD appeared together; and through painstaking genetic analysis they zeroed in on a key genetic trigger for both diseases. In 2011, their labs simultaneously identified a mutation in the C9orf72 gene. It is an expansion mutation – a repeat of the same six-letter sequence of DNA, occurring hundreds to thousands of times in affected individuals.

The discovery represents a landmark moment in the study of these diseases. This single mutation explains about a third of familial cases of both diseases in European populations, as well as more than five percent of cases in patients with no family history of the diseases. It sheds light on the disease mechanisms, pointing in particular to multiple effects of toxic RNA and proteins in brain cells. It has established ALS and FTD – previously considered two largely separate disorders – on a disease spectrum, sharing risk factors and molecular causes. And perhaps most significantly it has enabled genetic testing for affected families, and opened new pathways for the development of treatments for these currently incurable diseases – including at least two therapies currently undergoing clinical trials. While ALS and FTD remain incurable, thanks to the C9orf72 discovery they are now conditions with plausible molecular causes and promising therapeutic targets.

Breakthrough Prize in Mathematics

Frank Merle‘s work has significantly advanced the modern understanding of nonlinear evolution equations – the mathematical descriptions of how waves, fluids, and other dynamic systems change over time. His work has a particular focus on singularities: points where solutions to the equations surge to infinity. Alone and in collaborations, he has solved several fundamental problems, including proving that certain equations long thought to be well-behaved actually “blow up” – become infinite – in finite time.

Working on the soliton resolution conjecture (which predicts that any wave disturbance will eventually decompose into a set of stable, shape-preserving waves), Merle and Carlos Kenig, joined later by Thomas Duyckaerts, developed the powerful channels of energy technique coupled with the concentration compactness method. With Yvan Martel and Pierre Raphael, he revealed how singularities form in the KdV type equation (which describes various wave phenomena from shallow waves to rogue waves). Perhaps most remarkable is his work on the nonlinear version of the famous Schrödinger equation from quantum physics. In early work, he made a complete classification of all the ways this equation’s solutions can blow up. Later he proved, with Pierre Raphael, Igor Rodnianski, and Jérémie Szeftel, that the defocusing version of the equation – long believed to be inherently stable – can in fact blow up in finite time. This highly surprising result exploited an unexpected connection to fluid dynamics: it helped to resolve a major open problem, identifying smooth solutions to the compressible Euler and Navier-Stokes equations where the fluid’s density and velocity become infinite – representing a complete breakdown of the fluid description. Throughout his career, Merle’s insights have overturned fundamental assumptions in the field, forged deep connections between mathematics and physics, and opened new avenues toward some of the most celebrated unsolved problems.

Breakthrough Prize in Fundamental Physics

Across more than six decades, scientists and engineers from three “muon g-2” collaborations, representing dozens of institutions, have pushed experimental precision ever higher in pursuit of a single, very significant number: the anomalous magnetic moment of the muon. The muon is a heavy, unstable cousin of the electron, and like the electron it can behave like a tiny magnet. The physicists are looking to capture how the muon’s magnetic strength is subtly affected by the “foam” of virtual particles constantly popping in and out of empty space around it. Measuring the muon’s magnetism and comparing it to theoretical predictions allows physicists to test whether any unknown particles or forces are hidden in this foam. In other words, to probe for new physics beyond the Standard Model, our most successful theory of particles and forces.

The CERN collaboration’s pioneering storage ring experiments of the 1960s and 1970s first measured the anomalous magnetic moment with meaningful precision. Then in the 1990s, Brookhaven National Laboratory‘s reimagining of the experiment achieved a major improvement in precision. And after the audacious transportation of Brookhaven’s 50-ton, 15-meter-diameter storage ring 3,200 miles by road and barge to Fermilab in 2013, the experiment was systematically refined to achieve a final precision of 127 parts per billion – a mind-boggling 30,000 times more precise than the first g-2 experiment in 1965. The results had shown a tantalizing discrepancy with the value predicted by theory; and in 2023, Fermilab’s new results pushed that discrepancy close to the threshold considered evidence for new physics. Since then, the final, even more precise results, compared to newly evolved theoretical calculations narrowed the gap, but considerable uncertainty remains for the moment. Whatever the final verdict, this experiment represents a remarkable theoretical, experimental and technological endeavor, achieving extraordinary precision in the quest for fundamental understanding.

Special Breakthrough Prize in Fundamental Physics

David J. Gross has been a leading figure in fundamental physics for six decades. In the early 1970s, there was a gap in quantum field theory, our best theory of particles and forces. The theory could not describe or accurately predict the strong nuclear force, which holds the nucleus of the atom together. But in 1973, Gross and his graduate student Frank Wilczek (as well as, independently, David Politzer) solved the mystery. They discovered that the strong force works the opposite way to familiar forces like gravity: it gets weaker as particles approach each other, but stronger as they move apart. This explained why quarks, the particles inside the atomic nucleus, can never escape or be observed in isolation, and it enabled the development of quantum chromodynamics – the theory of the strong force and the final foundation stone of the Standard Model of particle physics.

Gross has gone on to make seminal contributions across multiple areas of theoretical physics. For example, he and his collaborators developed a simplified quantum field theory that helped explain how particles can acquire mass; and developed new theoretical approaches attempting to unify all fundamental forces, including gravity, in a single framework known as heterotic string theory.

Alongside his theoretical work, Gross has a longstanding record of leadership in the physics community, in roles including Director of the Kavli Institute for Theoretical Physics, and President of the American Physical Society. He has helped establish physics institutes in India, China, and South America. He directed the Jerusalem Winter School in Theoretical Physics and chaired the Solvay Physics Conferences for the last 25 years. In 2025 he was one of the authors of an ambitious 40-year plan for physics on behalf of the National Academies of Sciences, Engineering, and Medicine. And over the course of his career, he has been a mentor to numerous brilliant students who became leaders themselves, passing on his vision of physics as a collaborative international endeavor.

Inaugural Vera Rubin New Frontiers Prize

A new physics prize, the Vera Rubin New Frontiers Prize, will be announced during the ceremony, along with the inaugural recipient, Carolina Figueiredo, from Princeton University. One $50,000 prize is awarded this year; from 2027 there will be 3 per year.

The prize is named in tribute to the great astronomer Vera Rubin, who discovered key evidence for dark matter, and in homage to whom NVIDIA’s new chip platform is named. The new prize recognizes women physicists within two years of their PhDs who have already made important contributions to science.

Carolina Figueiredo discovered that three apparently unrelated theories — two governing nuclear particles called gluons and pions, and the third describing particles in a “toy model” that does not describe the existing world — all forbid exactly the same set of particle collisions. This was a big surprise, as the three theories are quite different, with no reason to think they are connected. Figueiredo’s discovery revealed that the common behavior reflects a single underlying geometric structure: curves drawn on surfaces, within a framework now known as surfaceology. Intriguingly, this structure makes no reference to particles moving through space and time; yet it reproduces the predictions of conventional physics far more efficiently than the traditional approach, which tracks each particle’s movement through these dimensions. Figueiredo’s work thus advances – and perhaps brings closer to the real world – a broader program to reformulate the foundations of particle physics in purely geometric terms, with spacetime as an emergent phenomenon arising from a new set of principles.

New Horizons in Physics Prize

Benjamin R. Safdi has made wide-ranging contributions to the search for the axion, a hypothetical particle that would explain a long-standing puzzle about the strong nuclear force, and could account for the mysterious dark matter that makes up 85 percent of the Universe’s mass. He has proposed ingenious new strategies for detecting axion-like particles using observations of astronomical objects, from radio emissions of neutron stars to X-rays from white dwarfs.

Clay Córdova, Thomas Dumitrescu, Shu-Heng Shao, and Yifan Wang have discovered and developed the theory of “generalized symmetries” in quantum field theory. Symmetries have long been among the most powerful tools in physics. The work of these researchers has shown that the Standard Model of particle physics, as well as other quantum field theories, possess previously unrecognised symmetry structures. Their work has opened a broad new field with applications ranging from falsifying theories beyond the Standard Model to simulating fundamental particles on a lattice.

Dillon Brout, J. Colin Hill, Mathew Madhavacheril, Maria Vincenzi, Daniel Scolnic, and W. L. Kimmy Wu have gleaned powerful new results from the two most important tools for measuring the expansion and composition of the Universe: the cosmic microwave background (CMB) radiation left over from the Big Bang, and light from exploding stars known as Type Ia supernovae. Hill, Madhavacheril, and Wu have pushed analyses of CMB data beyond previous limits, producing the most precise tests to date of the standard cosmological model as well as of gravitational lensing of the CMB – the subtle bending of light from the early Universe by the matter it passes on its way to us. Meanwhile Brout, Scolnic, and Vincenzi built and analysed the largest modern supernova datasets – including Pantheon+, now the most cited supernova analysis in cosmology – delivering tight constraints on dark energy and the rate of expansion of the cosmos.

New Horizons in Mathematics Prize

Otis Chodosh has settled several questions in differential geometry that had been open since the 1970s and 1980s. With Chao Li, he proved a central conjecture in the field concerning a broad class of higher-dimensional spaces known as “aspherical manifolds.” With Christos Mantoulidis, he resolved a key problem in geometric analysis of minimal surfaces – surfaces that locally minimise their area, like soap films.

Vesselin Dimitrov and Yunqing Tang have solved long-standing problems in number theory that had resisted all previous approaches. With Frank Calegari, they proved the “unbounded denominators conjecture,” about a fundamental class of objects known as modular forms, using methods that surprised experts in the field. Most recently, again with Calegari, they proved the irrationality of a number related to a basic infinite series – the first result of its kind since Apéry’s celebrated work forty-five years ago.

Hong Wang has resolved or made advances on a family of notoriously difficult problems in harmonic analysis – a branch of mathematics that studies functions by decomposing them into fundamental components. With Josh Zahl, she proved the Kakeya conjecture in three dimensions, one of the most famous open problems in the field: it concerns how much space is needed to rotate a needle through every possible direction.

Maryam Mirzakhani New Frontiers Prize

Amanda Hirschi has produced a number of significant papers in symplectic topology, a field studying higher-dimensional surfaces with a geometric structure that generalises the mathematics of classical mechanics. With co-authors, she developed a powerful new framework that leads to major simplifications in the foundations of Gromov-Witten theory. Anna Skorobogatova has made notable contributions in geometric measure theory, which uses techniques from analysis to tackle geometric problems such as finding surfaces of minimal area. In a series of papers with collaborators, she resolved a long-standing question about the structure of singularities of area-minimising surfaces, completing a programme that spanned over sixty years. Mingjia Zhang works on higher-dimensional objects in number theory called Shimura varieties. She provided a way to better understand the geometry of Mantovan’s celebrated “product formula” in number theory.

Citations for 2026 Laureates

2026 Breakthrough Prize in Life Sciences

Jean Bennett, University of Pennsylvania

Katherine A. High, University of Pennsylvania, Children’s Hospital of Philadelphia, and Rockefeller University

Albert Maguire, University of Pennsylvania

For developing a therapy for inherited retinal degeneration that became the first FDA-approved gene therapy for a genetic disease.

Rosa Rademakers, VIB, University of Antwerp, and Mayo Clinic

Bryan Traynor, National Institute on Aging, National Institutes of Health

For the discovery of the most common genetic cause of ALS and frontotemporal dementia which charted the path for new mechanistic studies of these diseases.

Stuart H. Orkin, Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute

Swee Lay Thein, National Heart, Lung and Blood Institute, National Institutes of Health

For elucidating the mechanism driving the switch from fetal to adult hemoglobin and validating it as a therapeutic target for sickle-cell disease and beta-thalassemia.

2026 Breakthrough Prize in Mathematics

Frank Merle, CY Cergy Paris Université and Institut des Hautes Études Scientifiques

For breakthroughs in nonlinear evolution equations, with regards to their stability, singularity formation, or resolution into solitons.

2026 Breakthrough Prize in Fundamental Physics

The Muon g-2 Collaborations at CERN, Brookhaven National Laboratory, and Fermilab

For multi-decade, groundbreaking contributions to the measurement of the muon’s anomalous magnetic moment, pushing the boundaries of experimental precision and igniting a new era in the quest for physics beyond the Standard Model.

2026 Special Breakthrough Prize in Fundamental Physics

David J. Gross, Kavli Institute for Theoretical Physics, University of California, Santa Barbara

For a lifetime of groundbreaking contributions to theoretical physics, from the strong force to string theory, and for tireless advocacy for basic science worldwide.

2026 Vera Rubin New Frontiers Prize

Carolina Figueiredo, Princeton University

For contributions to the geometric structure of scattering amplitudes, revealing hidden relations among quantum field theories.

2026 Maryam Mirzakhani New Frontiers Prize

Amanda Hirschi, IMJ-PRG, Sorbonne Université

For contributions to symplectic topology.

Anna Skorobogatova, Clay Research Fellow and ETH Zürich

For contributions to geometric measure theory.

Mingjia Zhang, Princeton University and Institute for Advanced Study

For contributions to the theory of Shimura varieties.

2026 New Horizons in Mathematics Prize

Otis Chodosh, Stanford University

For contributions to differential geometry and the calculus of variations, including work on minimal surfaces and manifolds with positive scalar curvature.

Hong Wang, Institut des Hautes Études Scientifiques and New York University

For work in harmonic analysis, partial differential equations, and geometric measure theory, including the local smoothing conjecture, Furstenberg set conjecture, and the Kakeya conjecture.

Vesselin Dimitrov, Caltech

Yunqing Tang, University of California, Berkeley

For work in Diophantine geometry, including the proof of the Atkin-Swinnerton-Dyer unbounded denominators conjecture and new irrationality results for special values of Dirichlet L-series (both joint with Frank Calegari).

2026 New Horizons in Physics Prize

Benjamin R. Safdi, University of California, Berkeley

For proposing new ways to seek axion-like particles with laboratory experiments and astronomical observations.

Clay Córdova, University of Chicago

Thomas Dumitrescu, Mani L. Bhaumik Institute for Theoretical Physics, UCLA

Shu-Heng Shao, MIT

Yifan Wang, New York University

For generalizing the notion of symmetry in various ways, and for exploring the consequences of these generalized symmetries, in quantum field theory, particle physics, condensed matter physics, string theory, and quantum information theory.

Dillon Brout, Boston University

J. Colin Hill, Columbia University

Mathew Madhavacheril, University of Pennsylvania

Maria Vincenzi, University of Oxford

Daniel Scolnic, Duke University

W. L. Kimmy Wu, Caltech

For advances in cosmic microwave background and supernovae cosmology.

Videos and Photos

Assets, including headshots of this year’s winners, can be downloaded for media use here.

Images and select video from the 2026 Breakthrough Prize Gala — red carpet and ceremony — can be downloaded for media use here.

The show will premiere on YouTube on Sunday, April 26th at 3PM Eastern / 12PM Pacific.

For the 14^th year, the Breakthrough Prize, renowned as the “Oscars® of Science,” recognizes the world’s top scientists. Each prize is $3 million and presented in the fields of Life Sciences, Fundamental Physics and Mathematics. In addition, up to three New Horizons in Physics Prizes, up to three New Horizons in Mathematics Prizes and up to three Maryam Mirzakhani New Frontiers Prizes are given out to early-career researchers each year. Laureates attend a gala award ceremony designed to celebrate their achievements and inspire the next generation of scientists.

The Breakthrough Prizes were founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Julia and Yuri Milner, and Anne Wojcicki and have been sponsored by foundations established by them. Selection Committees composed of previous Breakthrough Prize laureates in each field choose the winners. Information on the Breakthrough Prize is available at breakthroughprize.org.

View original content:https://www.prnewswire.co.uk/news-releases/breakthrough-prize-announces-2026-laureates-302746558.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

RSV is a common virus that can cause severe respiratory illness in infants and young children, including lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia. It is a leading cause of infant hospitalisation worldwide, with early-life infection linked to potential longer-term effects including recurrent wheeze or asthma, repeat hospital admissions and impaired lung health.

In England, a national maternal RSV vaccination programme was introduced on 1 September 2024, offering the Bivalent Prefusion F vaccine to pregnant women from 28 weeks’ gestation.

To evaluate its impact on infant hospitalisations due to RSV-associated LRTI, researchers from the UK Health Security Agency (UKHSA) conducted a retrospective cohort study using linked national datasets, including NHS maternity records, immunisation data and hospital and laboratory data. The analysis included 289,399 infants born between 2 September 2024 and 24 March 2025, representing around 90% of births in England during this period.

Across the study population, 4,594 RSV-associated hospitalisations were recorded. Although infants born to unvaccinated mothers made up 55% of the total cohort, they accounted for 87.2% of hospitalisations.

In contrast, infants whose mothers were vaccinated at least 14 days before birth had a markedly lower risk of hospitalisation, with vaccine effectiveness estimated at 81.3%, relative to the unvaccinated group.

Lead author and UKHSA epidemiologist Matt Wilson commented, “As the largest study to date examining the impact of this vaccine on infant hospitalisation, these findings provide robust evidence that vaccination offers substantial protection against severe illness in young infants. We found a clear relationship between timing and protection, with effectiveness increasing as the interval between vaccination and birth lengthens, reaching close to 85% when vaccination occurs at least four weeks before delivery.”

The study also investigated outcomes in preterm infants. Vaccine effectiveness was estimated at 69.4% in preterm infants, when allowing at least 14 days between vaccination and birth.  

“These findings are particularly important for preterm infants, who are among the most vulnerable to severe RSV infection,” added Wilson. “With sufficient time between vaccination and birth, we saw good levels of protection in these babies.”

View original content:https://www.prnewswire.co.uk/news-releases/escmid-global-maternal-rsv-vaccination-cuts-infant-hospitalisation-risk-by-over-80-major-ukhsa-study-finds-302740834.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

NEW YORK, April 17, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on April 17th

• Markets are up Friday morning after President Trump said late Thursday that the conflict in Iran “should be ending pretty soon.”
• Aevex (NYSE: AVEX) CEO Roger Wells will join NYSE Live this morning to discuss its strategy as the firm prepares to begin trading on the NYSE.
• Shares of Madison Air (NYSE: MAIR) popped by more than 17% in its first day of trading on the NYSE Thursday.
• Parker Institute of Cancer Immunotherapy CEO Karen Knudsen will join NYSE Live to elaborate on its collaboration with the Cancer Vaccine Coalition.

Opening Bell

Aevex (NYSE: AVEX) celebrates its IPO and NYSE debut

Closing Bell

Pinnacle West Capital (NYSE: PNW) marks its 65^th anniversary of listing

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Video – https://mma.prnewswire.com/media/2959306/NYSE_Market_Update_April_17.mp4 

Photo – https://mma.prnewswire.com/media/2959305/NYSE_Morgan_Stanley.jpg 

Logo – https://mma.prnewswire.com/media/2581322/5922833/New_York_Stock_Exchange_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-update-defense-tech-company-aevex-to-make-its-public-debut-302745917.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

While India has made significant progress in digital health infrastructure and acute care delivery, organised clinical models focused on upstream intervention, longitudinal health tracking, and foundational disease prevention remain limited. This partnership addresses that gap by combining Project Serotonin’s eighth-generation AI/ML-enabled precision health platform with Times of India Group’s consumer reach and understanding of the market, creating India’s first scalable system that delivers personalized longevity protocols designed around Indian health profiles, disease risk patterns, and lifestyle contexts.

Through this collaboration, Project Serotonin will power Humanedge Essentials, enabling thousands of individuals to access precision-guided health optimization that addresses the early biological drivers of chronic diseases, altering metabolic, cognitive, hormonal, and immune health long before symptoms appear. The platform translates complex biological data into actionable, continuously refined health protocols across nutrition, supplementation, sleep, exercise, fasting, and lifestyle interventions, informed by 44,000+ stratified clinical studies and 800,000+ individual data points per user.

A Pivotal Moment for India’s Healthcare Transformation

The partnership comes as India’s preventive healthcare sector experiences unprecedented growth, projected to reach $532 billion by 2030 at a 22% compound annual growth rate, significantly outpacing curative healthcare’s 15% trajectory, according to industry market analysis. As per a RedSeer survey, 35% of India’s population comprises health-conscious individuals, with 90% actively using health monitoring applications and devices, yet most lack access to clinically validated, precision-guided programs.

India is coping with an exploding health crisis while being at the intersection of burgeoning awareness of global preventive best practices, affordable testing infrastructure, and widespread technology access, creating ideal conditions for precision foundational health platforms to deliver measurable outcomes at scale. Just as India leapfrogged mobile connectivity and digital payments, this partnership positions health-conscious Indians to access precision foundational health rivaling premium longevity programs in mature markets around the world.

Anchit Saini, Business Head – Humanedge said, “We are proud to launch India’s first precision longevity program at scale, making evidence-based health optimization accessible to thousands of individuals who previously had no access to this level of personalized care. This has been made possible by deploying Project Serotonin’s revolutionary platform, which provides the scientific and technological foundation required to deliver individualized, longitudinal preventive care at scale. What’s been missing in India is a clinical system that connects diagnostics, genetics, continuous monitoring, and specialist guidance into one long-term view of foundational health. This is what we are building together.”

Shobini Kaveriappa, Co-founder and Head, Platform & User Success, Project Serotonin added, “This partnership with Times of India Group represents our vision of democratizing evidence-informed science through our world-class, global precision technology platform reaching consumers through best-in-class partners who provide the trust, expertise, commitment and human touch that sustainable health transformation requires. This is imperative as we leapfrog legacy health models and shift India’s healthcare paradigm toward early disease prevention and peak health, building a healthier, more productive nation at its population peak.”

About Humanedge 

Humanedge, by Times of India, is a trusted precision longevity company helping high-performing Indians take control of how they age.

We exist because India is living longer, but not necessarily better. Chronic stress, poor sleep, metabolic risk, hormonal imbalance, and declining energy are becoming the quiet tax on performance, health, and quality of life. Yet most healthcare still reacts after the damage is done. Humanedge combines deep diagnostics, personalised protocols and expert coaching to help people improve performance today while protecting health for the decades ahead. Our work spans sleep, nutrition, strength, stress, recovery and emotional resilience, brought together in one integrated journey.

About Project Serotonin

Built over ten years of R&D, with conviction that peak health can be achieved with precision science and cutting-edge technology, Project Serotonin’s eighth generation platform is powered by deep-learning algorithms that integrate genetics, blood biomarkers, nutrition, lifestyle, wearable data and behavioral metrics. The company runs extensive real-world pilots for every protocol before release and continuously optimizes outcomes for every single user.

Its multidisciplinary team of scientists and engineers have invested over 300,000 hours to precisely quantify micronutrients – exact formulations, dosages, frequency, combinations, exercise, sleep, fasting, diet, and lifestyle protocols that deliver precision results. Project Serotonin’s mission is to make measurable, outcomes-guaranteed peak health accessible to millions through trusted partners. For more information, visit: www.projectserotonin.com.

For more information, contact:

Madhura M I Email: madhura@sr.tn I Mobile: +91-6362970766

Logo: https://mma.prnewswire.com/media/2958323/Project_Serotonin_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/project-serotonin-in-pact-with-the-times-of-india-group-to-launch-indias-first-precision-longevity-program-humanedge-essentials-302745693.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.

#WHD2026       wfh.org/whd

“Accurate diagnosis is the gateway to care for people living with bleeding disorders. Yet in many parts of the world, barriers continue to delay or prevent proper diagnosis—leading to unacceptably low diagnosis rates. The challenge is even greater for people with von Willebrand disease, rare bleeding disorders, and for women and girls with bleeding disorders. On April 17, I call on the global community to unite in advocating for stronger diagnostic capabilities everywhere—because without diagnosis, there is no treatment, and without treatment, there is no progress.”

—Cesar Garrido, WFH President

World Hemophilia Day 2026 calls on governments, healthcare providers, and advocates around the world to take meaningful action to close the gap in diagnosing people with bleeding disorders. In many regions—and across several types of bleeding disorders—diagnosis is often delayed, leaving individuals without the treatment and care they urgently need. These delays can significantly impact health, quality of life, and long-term outcomes. By working together, we can confront these inequities and ensure that every person with a bleeding disorder receives a timely diagnosis—the first critical step toward access to care.

World Hemophilia Day is an opportunity for individuals, organizations, and communities to come together and make a difference. Here are some ways to participate:

• Contact your national patient association to find out how you and other members can work together on World Hemophilia Day and raise awareness for increasing diagnosis of bleeding disorders.
• Participate in the World Hemophilia Day Light it Up Red! campaign. Last year, thousands of people worldwide showed their support by lighting up over 175 landmarks red in cities across the world
• Support our global advocacy efforts and be a part of what we are building today for future generations by donating here
• Share your story about how your quality of life—or the quality of life of someone you know—has changed thanks to receiving a diagnosis, treatment and care on wfh.org/whd
• Get social by posting about inherited bleeding disorders on Facebook, X, LinkedIn and Instagram using the #WorldHemophiliaDay, #WHD2026 and #LightItUpRed hashtags
• Download resources like posters and social media banners from wfh.org/whd to help build your World Hemophilia Day Campaign
• Take action locally and use WFH World Hemophilia Day materials to send a letter to your local policymakers, set up meetings with elected officials and health ministers and engage with the local media
• Follow the WFH on our social channels and share our World Hemophilia Day content with the world

To learn more about World Hemophilia Day, please visit wfh.org/world-hemophilia-day.

The WFH would like to thank our World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., CSL Behring, F. Hoffman-La Roche Ltd., Grifols, Kedrion, LFB S.A, Novo Nordisk, Octapharma, Pfizer, Regeneron, Sanofi, Sobi, and Takeda.

About hemophilia and other bleeding disorders

In people with bleeding disorders, the blood clotting process doesn’t work properly, with the result that they can bleed for longer than normal, and some people may experience spontaneous bleeding into joints, muscles, or other parts of their bodies which can lead to developmental and permanent mobility issues.

About the World Federation of Hemophilia

The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support, and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. The WFH is founded upon the following core values and organizational principles: patients first, collaboration, integrity, respect, solidarity and excellence.

Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world.

To find out more about the WFH, please visit www.wfh.org.

Media contact: Neha Suchak, Director, Marketing & Communications, nsuchak@wfh.org, +1 514-875-7944, #2857

Logo – https://mma.prnewswire.com/media/2953328/World_Federation_of_Hemophilia_World_Hemophilia_Day_2026___April.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/world-hemophilia-day-2026—april-17-2026—diagnosis-first-step-to-care-302738741.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.